The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)



Gene Review

AVP  -  arginine vasopressin

Canis lupus familiaris

Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of AVP

  • These results demonstrate that the enhanced release of AVP during hemorrhage with ANS blockade can be mediated either by cardiac or arterial baroreceptors; however, the maximum response is elicited only when both sets of receptors are functioning normally [1].
  • In summary, NHX attenuated the ACTH response to hypotension (large peripheral AVP response) but not to INS or CRF (small peripheral AVP response).(ABSTRACT TRUNCATED AT 250 WORDS)[2]
  • AVP infusion restored renal blood flow and Do2 in endotoxic shock compared with animals resuscitated with NE, which had persistently low renal blood flow and Do2 [3].
  • Chronic chloride depletion alkalosis in dogs causes a lowered osmotic threshold and increased sensitivity for vasopressin (AVP) release [4].
  • CRH, AVP, IGF-I and cortisol had no effect on the proliferation of canine pituitary cells or canine corticotrophic adenoma cells [5].

Psychiatry related information on AVP

  • Since AVP release and drinking behavior normally are closely associated over a narrow range of changes in plasma osmolality (Posm), we investigated whether alkalotic dogs would also show an altered responsiveness to the dipsogenic effects of angiotensin II (ANG II) and osmotic stimuli [4].

High impact information on AVP

  • In competition binding experiments with [3H]-SK&F 101926 using cell and liver membranes, guanosine 5'-(beta,gamma-imido)triphosphate did not significantly alter the affinity of the V1 antagonist d(CH2)5Tyr(Me)AVP, but the affinity of AVP was decreased [6].
  • Treatment with either 10 microM CPA or 1 mM ATP also caused an increase in UT-A2-mediated urea flux, although these responses where transient compared with those induced by AVP or elevated cAMP [7].
  • We found that AVP decreased the lumen diameter of microperfused afferent arterioles dose-dependently and that a V1 antagonist, OPC21268, inhibited the vasoconstrictor action of AVP [8].
  • We have previously reported that vasopressin (AVP) V2 receptor stimulation increased renal blood flow in dogs anesthetized with pentobarbital [8].
  • These results suggest that AVP V2 receptors are present in rabbit afferent arterioles and that V2 receptor stimulation induces vasodilation in rabbit afferent arterioles [8].

Chemical compound and disease context of AVP


Biological context of AVP

  • Barium, in the presence of AVP and IBMX, depolarized the cell membrane potential (bis-oxonol fluorescence increased 22.3 +/- 0.03%), reversed secretion to absorption (from 3.21 +/- 0.93 to -1.52 +/- 0.61 x 10(-6) ml/min/cm2), and increased cell volume 2.7 +/- 0.5% [12].
  • In the absence of AVP and IBMX bumetanide had no effect on fluid transport, cell volume or membrane potentials [12].
  • SAP stimulation or AVP stimulation selectively decreased heart rate or increased atrioventricular conduction time, respectively [13].
  • The data demonstrate that opiate receptors behind the BBB are primarily involved in kappa agonist-induced water diuresis and possibly inhibition of AVP secretion [14].
  • The time to maximal ankle venous pressure after standing (VFT) and to 90% of that time after exercise (VRT90), and the minimal pressure after exercise (AVP) were measured in 17 greyhounds before intervention, after only the superficial femoral vein valve remained (n = 5), and after complete lower limb venous valvulotomy (n = 17) [15].

Anatomical context of AVP

  • Distension of the left atrium led within 2 min to a fall in plasma AVP concentration which reached a steady lower value within 4 min [16].
  • However, median eminence staining for AVP and neurophysin was greatly diminished in neurohypox dogs [17].
  • Immediately after single superficial femoral vein valve construction, VFT, AVP, and VRT90 measurements were not significantly different from normal [15].
  • Data suggest that kappa opioid agonist-induced water diuresis involves inhibition of vasopressin (AVP) secretion; however, it is not clear whether this action involves kappa receptors in the neurohypophysis or receptors behind the blood-brain barrier (BBB) [14].
  • In contrast, camostat mesilate is slowly absorbed (8%/hr) and could inhibit the proteolytic activity in the nasal mucosa, resulting in enhanced nasal absorption of AVP and 1-d-8-DAVP [18].

Associations of AVP with chemical compounds

  • Plasma vasopressin (AVP) concentration in dogs anaesthetized with chloralose was measured by radioimmunoassay and was within the range of 2-5 pg/ml. during control periods [16].
  • However, the ACTH and aldosterone responses to 5 ng/kg.min angiotensin II infusion iv were attenuated in neurohypox dogs off AVP replacement [17].
  • However, AVP 10(-8) M increased the lumen diameter of norepinephrine (NE)-constricted afferent arterioles pretreated with OPC21268 (OPC + NE, 8.2 +/- 0.7 microns; OPC + NE + AVP, 9.9 +/- 0.9 microns*; *P < 0.05, N = 13) [8].
  • AVP and IBMX changed the direction of net fluid transport to secretion (4.24 +/- 0.49 x 10(-6) ml/min/cm2) [12].
  • This vasodilatory effect of AVP was abolished by pretreatment with a V2 antagonist, OPC31260 [8].

Other interactions of AVP

  • The nature of the activity of vasopressin which is responsible for the inhibition of renin secretion was studied by comparing the effects of vasopressin (AVP) and analogs of AVP in anesthetized water-loaded dogs [19].

Analytical, diagnostic and therapeutic context of AVP

  • Three weeks after transplantation the AVP measurements were consistent with an insufficient venous system, whereas the VRT90 measurements were between and statistically different from both the control and totally incompetent system (p less than 0.05) [15].
  • TWI per kg body weight ( TWI X kg-1) after 90 min was significantly correlated with the osmolalities and AVP levels in plasma and CSF prior to rehydration [20].
  • Simultaneous intravenous infusion of AVP (12.5 ng/min) had a small, augmenting effect on the ACTH response to NP (peak ACTH 120 +/- 27 pg/ml) [21].
  • After denervation, neither AVP infusion at 0.2 (3.0 +/- 0.5 to 2.4 +/- 0.4 ng X ml-1 X 3 h-1) nor 1.0 ng X kg-1 X min-1 (3.1 +/- 0.8 to 2.8 +/- 1.0 ng X ml-1 X 3 h-1) suppressed PRA.(ABSTRACT TRUNCATED AT 250 WORDS)[22]
  • Adrenalectomy attenuated AVP response to hemorrhagic hypotension [10].


  1. Contribution of cardiac and arterial baroreceptors to enhanced vasopressin release during hemorrhage with autonomic blockade. Zhu, J.L., Leadley, R.J. Proc. Soc. Exp. Biol. Med. (1995) [Pubmed]
  2. ACTH and vasopressin responses to insulin-induced hypoglycemia in intact and neurohypophysectomized conscious dogs. Raff, H., Papanek, P.E., Cowley, A.W. Neuroendocrinology (1991) [Pubmed]
  3. Vasopressin vs norepinephrine in endotoxic shock: systemic, renal, and splanchnic hemodynamic and oxygen transport effects. Guzman, J.A., Rosado, A.E., Kruse, J.A. J. Appl. Physiol. (2003) [Pubmed]
  4. Altered drinking responses in dogs with chronic metabolic alkalosis. Kucharczyk, J., Jamshaid, A., Lemoine, J. Peptides (1988) [Pubmed]
  5. Effects of corticotrophin-releasing hormone, vasopressin and insulin-like growth factor-I on proliferation of and adrenocorticotrophic hormone secretion by canine corticotrophic adenoma cells in vitro. van Wijk, P.A., Rijnberk, A., Croughs, R.J., Meij, B.P., Mol, J.A. Eur. J. Endocrinol. (1998) [Pubmed]
  6. A novel radiolabeled vasopressin antagonist: [3H-Phe]-desGlyd(CH2)5D-Tyr(Et)VAVP, [3H]-SK&F 101926. Stassen, F.L., Heckman, G., Schmidt, D., Nambi, P., Aiyar, N., Landvatter, S., Crooke, S.T. Mol. Pharmacol. (1987) [Pubmed]
  7. Urea flux across MDCK-mUT-A2 monolayers is acutely sensitive to AVP, cAMP, and [Ca2+]i. Potter, E.A., Stewart, G., Smith, C.P. Am. J. Physiol. Renal Physiol. (2006) [Pubmed]
  8. Vasodilation induced by vasopressin V2 receptor stimulation in afferent arterioles. Tamaki, T., Kiyomoto, K., He, H., Tomohiro, A., Nishiyama, A., Aki, Y., Kimura, S., Abe, Y. Kidney Int. (1996) [Pubmed]
  9. Potentiated hormonal responses in a model of traumatic injury. DeMaria, E.J., Lilly, M.P., Gann, D.S. J. Surg. Res. (1987) [Pubmed]
  10. Responses of vasopressin and enkephalins to hemorrhage in adrenalectomized dogs. Inoue, M., Kimura, T., Matsui, K., Ota, K., Shoji, M., Iitake, K., Yoshinaga, K. Am. J. Physiol. (1987) [Pubmed]
  11. Vasopressin, ACTH, and corticosteroids during hypercapnia and graded hypoxia in dogs. Raff, H., Shinsako, J., Keil, L.C., Dallman, M.F. Am. J. Physiol. (1983) [Pubmed]
  12. Coupling of cell volume and membrane potential changes to fluid secretion in a model of renal cysts. Sullivan, L.P., Wallace, D.P., Grantham, J.J. Kidney Int. (1994) [Pubmed]
  13. Parasympatholytic effects of vecuronium are mediated by nicotinic and muscarinic receptors in hearts of anesthetized dogs. Narita, M., Furukawa, Y., Murakami, M., Takei, M., Ren, L.M., Chiba, S. J. Pharmacol. Exp. Ther. (1992) [Pubmed]
  14. Opiate receptors within the blood-brain barrier mediate kappa agonist-induced water diuresis. Brooks, D.P., Giardina, G., Gellai, M., Dondio, G., Edwards, R.M., Petrone, G., DePalma, P.D., Sbacchi, M., Jugus, M., Misiano, P. J. Pharmacol. Exp. Ther. (1993) [Pubmed]
  15. Venous valvular insufficiency: influence of a single venous valve (native and experimental). Dalsing, M.C., Lalka, S.G., Unthank, J.L., Grieshop, R.J., Nixon, C., Davis, T. J. Vasc. Surg. (1991) [Pubmed]
  16. Plasma vasopressin concentration in the anaesthetized dog before, during and after atrial distension. Ledsome, J.R., Ngsee, J., Wilson, N. J. Physiol. (Lond.) (1983) [Pubmed]
  17. Control of adrenocorticotropin secretion and adrenocortical sensitivity in neurohypophysectomized conscious dogs: effects of acute and chronic vasopressin replacement. Raff, H., Merrill, D.C., Skelton, M.M., Brownfield, M.S., Cowley, A.W. Endocrinology (1988) [Pubmed]
  18. Effects of proteolytic enzyme inhibitors on the nasal absorption of vasopressin and an analogue. Morimoto, K., Yamaguchi, H., Iwakura, Y., Miyazaki, M., Nakatani, E., Iwamoto, T., Ohashi, Y., Nakai, Y. Pharm. Res. (1991) [Pubmed]
  19. Role of antidiuretic activity in the inhibition of renin secretion by vasopressin in anesthetized dogs. Schwartz, J., Ott, C., Morales, O., Reid, I.A. Peptides (1986) [Pubmed]
  20. Plasma and cerebrospinal fluid vasopressin and osmolality in relation to thirst. Szczepańska-Sadowska, E., Simon-Oppermann, C., Gray, D.A., Simon, E. Pflugers Arch. (1984) [Pubmed]
  21. The effect of intracarotid vasopressin infusion on ACTH release in neurohypophysectomized, conscious dogs. Raff, H., Papanek, P.E., Liard, J.F., Cowley, A.W. Am. J. Physiol. (1994) [Pubmed]
  22. Effect of renal denervation on the suppression of renin secretion by vasopressin in conscious dogs. Gregory, L.C., Reid, I.A. Am. J. Physiol. (1984) [Pubmed]
WikiGenes - Universities